Alx Oncology Holdings (ALXO) EBT Margin (2019 - 2020)
Alx Oncology Holdings (ALXO) posted EBT Margin of 2146.3% for Q2 2020, down 157.95% sequentially from 832.06% in Q1 2020, and down 182282.0% YoY from N/an in Q3 2019.
Powered by 
Analysis
Alx Oncology Holdings (ALXO) EBT Margin (2019 - 2020) Analysis & Trends
Alx Oncology Holdings has reported EBT Margin for 2 years, with the latest figure at 2146.3% in Q2 2020.
- Quarterly EBT Margin fell 182282.0% year-over-year to 2146.3% in Q2 2020, while the trailing twelve-month figure through Mar 2021 was 10291.08% (down 1028185.0% YoY) and the FY2020 annual result came in at 3849.32%, down 386627.0% from the prior year.
- EBT Margin fell to 2146.3% in Q2 2020 per ALXO's latest filing, from 832.06% in the prior quarter.
- Over five years, EBT Margin peaked at 1011.29% in Q4 2019 and troughed at 2146.3% in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 12.09% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -2.67% |
| 10 | Alx Oncology Holdings | 273.99 Mn | 273.99 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2020 | -2,146.30% |
| Mar 31, 2020 | -832.06% |
| Dec 31, 2019 | -706.35% |
| Sep 30, 2019 | -241.72% |
| Jun 30, 2019 | -323.47% |